Artal Group S.A. Allovir, Inc. Transaction History

Artal Group S.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$3.17 - $5.82 $3.23 Million - $5.94 Million	1,020,000 Added 18.29%	6,597,167 $22.4 Million
Q3 2022 Nov 14, 2022	BUY	$4.13 - $8.79 $13.4 Million - $28.6 Million	3,253,796 Added 140.05%	5,577,167 $44 Million
Q3 2020 Nov 13, 2020	BUY	$21.05 - $42.7 $48.9 Million - $99.2 Million	2,323,371 New	2,323,371 $63.9 Million

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $40.9M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.